Co-Diagnostics, Inc.
CODX
Rank in Stocks
#31904
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops,... Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Share Price
$0.319
Last synced: 2026-11-09
Market Cap
$2.38M
Change (1 day)
24.22%
Change (1 year)
-97.30%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Co-Diagnostics, Inc. (CODX)
Category
Healthcare
EPS for Co-Diagnostics, Inc. (CODX)
EPS as of June 2026 TTM: $-26.72
According to Co-Diagnostics, Inc.'s latest financial reports, its current EPS (TTM) is $-26.72. At the end of 2025 the company had an EPS of $-35.25, an increase over its 2024 EPS of $-37.20.
EPS history for Co-Diagnostics, Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-26.72 | -24.20% |
| 2025 | $-35.25 | -5.24% |
| 2024 | $-37.20 | 3.33% |
| 2023 | $-36.00 | 165.29% |
| 2022 | $-13.57 | -135.62% |
| 2021 | $38.10 | 2,296.23% |
| 2020 | $1.59 | -114.34% |
| 2019 | $-11.09 | -26.07% |
| 2018 | $-15.00 | -20.63% |
| 2017 | $-18.90 | 270.59% |
| 2016 | $-5.10 | -5.56% |
| 2015 | $-5.40 | 38.46% |
| 2014 | $-3.90 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -158.61% |
US
|
|
| $-7.07 | -73.54% |
US
|
|
| $-5.29 | -80.20% |
AU
|
|
| $12.88 | -148.20% |
BE
|
|
| $21.56 | -180.69% |
NL
|
Questions about Co-Diagnostics, Inc.'s earnings per share (EPS)
What is Co-Diagnostics, Inc.'s earnings per share (EPS)?
Co-Diagnostics, Inc.'s earnings per share (EPS) over the last twelve months is $-26.72, as of Jun 2026.
What was Co-Diagnostics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Co-Diagnostics, Inc.'s earnings per share (EPS) was $-35.25, compared with $-37.20 in 2024.
How has Co-Diagnostics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Co-Diagnostics, Inc.'s earnings per share (EPS) was highest in 2021 ($38.10) and lowest in 2024 ($-37.20).
How does Co-Diagnostics, Inc.'s earnings per share (EPS) compare with similar companies?
Co-Diagnostics, Inc.'s earnings per share (EPS) ($-26.72) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.